Dr Emily Whitehouse is the latest neuromuscular consultant to join the fight against DMD at the Royal Manchester Children’s Hospital (RMCH). The RMCH is part of the DMD Hub network, running clinical trials for DMD treatments. Read more
Duchenne UK is delighted to announce that Vamorolone, a drug to treat Duchenne muscular dystrophy developed as an alternative to corticosteroids, has shown positive results in a Phase 2 Study. Read more
Duchenne UK is committed to the ongoing success of the DMD Hub and today announced a further four years of funding for the DMD Hub Manager role, bringing total investment in the DMD Hub to £4.3million. Read more
Pfizer has announced that the first UK-based DMD patient has been enrolled in a gene therapy trial at a DMD Hub site Read more
Duchenne UK have funded a study that aims to improve our knowledge of treating heart muscle disease in patients with Duchenne muscular dystrophy (DMD). Read more
Pharmaceutical companies Santhera Pharmaceuticals and ReveraGen BioPharma have announced new data from their clinical study of a potential treatment for Duchenne muscular dystrophy (DMD) that could replace the current standard of care, corticosteroids. Read more
DMD Care UK have launched the first comprehensive patient survey aiming to understand Duchenne muscular dystrophy (DMD) patients’ and caregivers’ experiences of medical care. Read more
Duchenne UK has invested £287,500 into a new 18-month study investigating whether Lipid Nanoparticles (LNPs) could be used to help in gene therapy treatments for DMD. Read more
Duchenne UK is partnering with Pathfinders Neuromuscular Alliance to address the lack of choice and control over accessible housing for people with DMD and other muscle-weakening conditions. Read more
This week we were delighted to have been featured in a publication from the National Institute for Health Research (NIHR), who have highlighted one of our major projects, the DMD Hub, as an example of how they work alongside industry to support clinical trials. Read more
A statement from four neuromuscular clinicians confirms that COVID-19 vaccines can be taken by people with DMD, and encourage those who are eligible to take it. Read more
Translarna, a drug that can help treat an underlying cause of Duchenne muscular dystrophy, has been accepted for use on NHSScotland. Read more